ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24 to 27. The event brought together leading global experts to discuss cutting-edge advances in basic hematology, immunology, stem cell biology, and cellular and gene therapies. One of the highlights of the meeting was the China–Japan Joint Symposium on Stem Cell and Cell Therapy, which drew significant attention. Professor Xue Feng from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), delivered an insightful presentation titled “Adeno-Associated Virus Vector Expressing Factor IX Padua in Treating Hemophilia B in China.” Following the presentation, Oncology Frontier – Hematology Frontier conducted an exclusive interview with Professor Xue to explore this innovative approach and its future clinical prospects.
Professor Juan Li: Evaluation and Management Strategies for Kidney Injury During Targeted Plus Immunotherapy in Advanced Renal Cell Carcinoma
Editor’s Note: With targeted therapy plus immunotherapy (“targeted-immunotherapy” or T+I) now established as the standard of care for advanced renal cell carcinoma (RCC), treatment-related nephrotoxicity has become an increasingly prominent…
Giuseppe Curigliano on the Clinical Impact and Future of T-DXd Combo Therapy | CSCO 2025
Editor's Note: The Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in Jinan. This conference brought together authoritative experts in the field of oncology from home and…
Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025
The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O'Connor, delivered a splendid presentation on the topic "REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL BASIS COMES INTO FOCUS." He systematically reviewed the historical challenges in the treatment of T-cell lymphoma and emphatically elaborated on why epigenetic targeting will be the key to turning the tide, pointing to a hopeful new path for the future treatment of this disease.
Summary Report of the International Workshop on Cell Therapy for Blood Diseases
The International Workshop on Cell Therapy for Blood Diseases, hosted by the Department of International Cooperation of the Ministry of Science and Technology of China, and organized by the Institute…